NRx Pharmaceuticals (NasdaqCM:NRXP) Q4 2025 Earnings call March 24, 2026 08:00 AM ET Company ParticipantsJonathan Javitt - Founder, Chairman and CEOMichael Abrams - CFOPatrick R. Trucchio - Managing Director of Equity ResearchConference Call ParticipantsEdward Moon - AnalystThomas Shrader - Managing Director and Senior Biotechnology Equity Research AnalystOperatorMorning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals Q4 2025 Results Conference Call. At this time, all lines are in listen-only ...

NRx Pharmaceuticals (NasdaqCM:NRXP) Q4 2025 Earnings call March 24, 2026 08:00 AM ET Company ParticipantsJonathan Javitt - Founder, Chairman and CEOMichael Abrams - CFOPatrick R. Trucchio - Managing Director of Equity ResearchConference Call ParticipantsEdward Moon - AnalystThomas Shrader - Managing Director and Senior Biotechnology Equity Research AnalystOperatorMorning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals Q4 2025 results conference call. At this time, all lines are in listen-only ...

Symptom Score Gains And Durable Culture ConversionThe ENCORE study’s results indicate that Arikayce (amikacin liposome inhalation suspension), in combination with a multidrug therapy, met its primary and all secondary endpoints, showcasing its potential to benefit patients with Mycobacterium avium complex lung infections.MAC lung infection is a chronic, often indolent respiratory illness caused by environmental bacteria (soil/water).The study met primary and all multiplicity-controlled secondary culture con ...

Sarepta Seeks Regular FDA ApprovalsThe stock’s decline comes as the company plans to submit supplemental new drug applications to the U.S. Food and Drug Administration (FDA) by the end of April, as detailed in the regulatory update.Sarepta requested a meeting with the FDA to discuss submitting supplemental new drug applications (sNDA) seeking conversion of the accelerated approvals of AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen) to traditional approvals.Sarepta received FDA confirmation that it can s ...

Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Signage is pictured in the main lobby of GSK offices in London, Britain, February 20, 2025. REUTERS/Chris J. Ratcliffe/File Photo Purchase Licensing Rights, opens new tab Companies GSK plc US FDA approves GSK's drug for liver disease-related itching | Reuters Skip to main content The company did not immediately respond to Reuters request for comment on pricing and availability details. Reporting by Sriparna Roy an ...

Core Insights - Inovio Pharmaceuticals is targeting an October 30 PDUFA date for the approval of INO-3107, which is positioned as a potential treatment for adults with recurrent respiratory papillomatosis (RRP) [2] - The company has successfully extended its cash runway into the fourth quarter of 2026, indicating financial stability and operational continuity [2] Management View - CEO Jacqueline Shea emphasized the significance of the upcoming BLA for INO-3107, highlighting the excitement surrounding the potential treatment for RRP [2]

Core Insights - Regeneron Pharmaceuticals and Sanofi received a positive opinion from the CHMP for expanding Dupixent's use in treating moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years [1][5] - A final decision from the European Commission is anticipated in the coming months [1] - Dupixent is already approved for CSU in adults and adolescents aged 12 years and older since November 2025 [2] Product Performance - Dupixent is currently approved for multiple conditions including asthma, atopic dermatitis, and chronic rhinosinusitis across various age groups [3] - The drug is not yet approved in the U.S. for the pediatric CSU population, with a decision expected by April 2026 [4] - In 2025, Dupixent generated global sales of $17.8 billion for Sanofi, reflecting a 26% year-over-year increase [10] Clinical Data - The CHMP's recommendation is based on data from two late-stage studies showing significant reductions in itch and hives at 24 weeks [5][8] - Dupixent improved disease control and increased the percentage of patients achieving well-controlled disease compared to placebo [8] Financials and Collaboration - Regeneron recorded $5.9 billion in collaboration revenues from Sanofi in 2025, marking a 30% year-over-year growth [10] - The collaboration agreement allows Sanofi to record global net product sales while Regeneron records its share of profits or losses [9]

Core Insights - Axsome Therapeutics has shown significant market performance over the past five years, driven by clinical and regulatory advancements, and is approaching large-cap status [1] - There remains potential for further investment in Axsome Therapeutics due to ongoing growth and new product developments [1] Group 1: Sales Growth - Axsome's revenue for the third quarter reached $171 million, reflecting a 63% increase compared to the same period last year [2] - The company's current product lineup includes Auvelity for depression, Sunosi for narcolepsy-related daytime sleepiness, and Symbravo for migraines, all contributing to strong sales growth [2][3] Group 2: Future Approvals - Axsome is pursuing new approvals and label expansions, including a new indication for Auvelity in treating Alzheimer's disease agitation, which has shown positive results in phase 3 studies and is under FDA consideration [4] - Sunosi has completed a phase 3 study for ADHD in adults, with plans for additional late-stage trials in related markets [5] Group 3: New Product Pipeline - The company is developing several other products, such as AXS-12 for cataplexy in narcolepsy and AXS-14 for fibromyalgia, which could significantly enhance sales potential [6] - The addressable market for Alzheimer's agitation is substantial, with over 5 million patients in the U.S. and currently only one FDA-approved treatment available [7]

Core Viewpoint - BioMarin Pharmaceutical is expected to report its Q4 and full-year 2025 results soon, with potential strong performance from its rare-disease drug Voxzogo, but there are also concerns regarding competition and revenue guidance [1][2][3][10]. Financial Performance - BioMarin's CFO indicated that Voxzogo revenue is projected to reach its highest level in Q4, contributing to an optimistic outlook for the quarter [2]. - The company raised the lower end of its 2025 revenue guidance to $3.15 billion, reflecting double-digit year-over-year growth expectations [3]. Upcoming Catalysts - The FDA has set a PDUFA date of February 28, 2026, for Palynziq's approval for adolescents with phenylketonuria, with potential EU approval also expected in the first half of the year [4]. - BioMarin plans to announce results from two Phase 3 clinical studies in the first half of 2026 and intends to file for full FDA approval of Voxzogo for achondroplasia [5]. Market Data - BioMarin's current market capitalization is $11 billion, with a gross margin of 80.64% [7]. - The stock is currently trading at $56.51, with a day's range of $55.30 to $56.72 [6][7]. Investment Considerations - There are reasons to be cautious, including reliance on large contracted ex-U.S. orders for Voxzogo, which if not fulfilled, could lead to missing Q4 estimates [8]. - Long-term uncertainty exists regarding Voxzogo's market position due to potential competition, which could impact future revenue projections [9]. - The acquisition of Amicus Therapeutics is seen as a potential growth booster, but waiting to invest may be prudent given current uncertainties [10].

Marty McCary, commissioner of the FDA. Welcome to San Francisco. >> Great to be here, Dave. Good to be with you. >> Yeah, thanks. It's JP Morgan Healthcare Conference this week in San Francisco. Considered, I think, probably the biggest most important biotech conference globally. Very important week. So, you're visiting this week for the conference. >> Yeah. 120,000 people, great conversations. You hear from everybody. Just not enough time to meet with everybody you want to meet with, but it's a great time. ...